These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19806664)

  • 1. A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin.
    Gordon DJ; Sloan SR; de Jong JL
    Am J Hematol; 2009 Nov; 84(11):771-2. PubMed ID: 19806664
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease.
    Luban NL; Wong EC; Henrich Lobo R; Pary P; Duke S
    Transfusion; 2015 Jul; 55 Suppl 2():S90-4. PubMed ID: 26174904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebral infarction after high-dose intravenous immunoglobulin therapy for Kawasaki disease.
    Wada Y; Kamei A; Fujii Y; Ishikawa K; Chida S
    J Pediatr; 2006 Mar; 148(3):399-400. PubMed ID: 16615977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pediatric use of intravenous immunoglobulins in immunomodulation. Apropos of 34 cases. Current data].
    Rapin F; Astruc J; Echenne B; Rodière M
    Ann Pediatr (Paris); 1988 Sep; 35(7):481-8. PubMed ID: 3178111
    [No Abstract]   [Full Text] [Related]  

  • 5. [Aseptic meningitis secondary to intravenous immunoglobulin treatment in Kawasaki disease].
    García Norniella B; Morán Poladura M; Fernández Díaz M; Fernández Fernández E; Suárez Castañón C
    An Pediatr (Barc); 2011 Jul; 75(1):79-80. PubMed ID: 21420919
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiology patient pages. Kawasaki disease.
    Baker AL; Newburger JW
    Circulation; 2008 Aug; 118(7):e110-2. PubMed ID: 18695195
    [No Abstract]   [Full Text] [Related]  

  • 7. Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease.
    Khan S; Doré PC; Sewell WA
    Pediatr Allergy Immunol; 2008 Mar; 19(2):186-7. PubMed ID: 18257907
    [No Abstract]   [Full Text] [Related]  

  • 8. [Intravenous administration of immunoglobulin speeds up improvement in Kawasaki disease].
    Fasth A; Andersson J; Elinder G
    Lakartidningen; 1990 Dec; 87(50):4315-7. PubMed ID: 1704086
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute hemolysis secondary to high-dose intravenous immunoglobulin in a patient with Stevens-Johnson syndrome.
    Shakouri AA; Bahna SL
    Ann Allergy Asthma Immunol; 2012 Jun; 108(6):463-4. PubMed ID: 22626604
    [No Abstract]   [Full Text] [Related]  

  • 10. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports.
    Padmore R
    Transfusion; 2015 Jul; 55 Suppl 2():S59-64. PubMed ID: 26174898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient characteristics and intravenous immunoglobulin product may affect eosinophils in Kawasaki disease.
    Kuo HC; Wang CL; Wang L; Yu HR; Yang KD
    Pediatr Allergy Immunol; 2008 Mar; 19(2):184-5. PubMed ID: 18257906
    [No Abstract]   [Full Text] [Related]  

  • 12. Incomplete Kawasaki disease: a pediatric diagnostic conflict.
    Celik U; Alhan E; Arabaci F
    Anadolu Kardiyol Derg; 2007 Sep; 7(3):343-4. PubMed ID: 17785242
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease.
    Nakagawa M; Watanabe N; Okuno M; Kondo M; Okagawa H; Taga T
    Am J Hematol; 2000 Mar; 63(3):160-1. PubMed ID: 10679809
    [No Abstract]   [Full Text] [Related]  

  • 14. Complementary use of passive surveillance and Mini-Sentinel to better characterize hemolysis after immune globulin.
    Winiecki S; Baer B; Chege W; Jankosky C; Mintz P; Baker M; Woodworth T; Nguyen M
    Transfusion; 2015 Jul; 55 Suppl 2():S28-35. PubMed ID: 26174895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An elevated value of high mobility group box 1 is a potential marker for poor response to high-dose of intravenous immunoglobulin treatment in patients with Kawasaki syndrome.
    Eguchi T; Nomura Y; Hashiguchi T; Masuda K; Arata M; Hazeki D; Ueno K; Nishi J; Kawano Y; Maruyama I
    Pediatr Infect Dis J; 2009 Apr; 28(4):339-41. PubMed ID: 19238112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of intravenous immunoglobulins in pediatric diseases.
    Ramasubramanian KV; Kumar A; Kabra SK; Seth V
    Indian Pediatr; 1999 Jan; 36(1):51-63. PubMed ID: 10709123
    [No Abstract]   [Full Text] [Related]  

  • 17. gamma-Globulin-induced modulation with necrotic-like morphology of peripheral blood neutrophils.
    Sugita K; Hirao J; Arisaka O; Eguchi M
    Eur J Pharmacol; 2005 Apr; 513(1-2):141-4. PubMed ID: 15878719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-classical Kawasaki disease in a 2 month old infant.
    Hartmann I; Weiss K; Bistritzer T; Baram S; Goldman M
    Isr Med Assoc J; 2006 Aug; 8(8):581-2. PubMed ID: 16958253
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006.
    Son MB; Gauvreau K; Ma L; Baker AL; Sundel RP; Fulton DR; Newburger JW
    Pediatrics; 2009 Jul; 124(1):1-8. PubMed ID: 19564276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical analysis of 36 cases of incomplete Kawasaki disease].
    Zou CX
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):397-8. PubMed ID: 18554478
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.